LIMITED OFFER
Save 50% on book bundles
Immediately download your ebook while waiting for your print delivery. No promo code needed.
Treatment Landscape of Targeted Therapies in Oncology
Challenges and Opportunities
- 1st Edition - July 29, 2023
- Editors: Pawan Kumar Maurya, Vikas Saini
- Language: English
- Paperback ISBN:9 7 8 - 0 - 4 4 3 - 1 6 0 3 4 - 9
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 1 6 0 3 5 - 6
Treatment Landscape of Targeted Therapies in Oncology: Challenges and Opportunities provides up-to-date knowledge on antitumor-targeted therapies and immunotherapy. The book's… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteTreatment Landscape of Targeted Therapies in Oncology: Challenges and Opportunities provides up-to-date knowledge on antitumor-targeted therapies and immunotherapy. The book's chapters are written by researchers dynamically working/focusing on cancer treatment. The content is designed to help those who are new to the field (beginners) and various specialized scientists and researchers involved in cancer research. For decades, the hallmark of cancer treatment has been conventional chemotherapy. But with the rapid increase in our understanding of the immune system, more and more small molecules, peptides, recombinant antibodies, vaccines and cellular therapeutic modalities are being applied to manipulate the immune response for cancer treatment.
- Covers basic concepts and updated knowledge of the latest anticancer drugs
- Brings comprehensive understanding of the treatment of cancer in context of immunotherapy and targeted therapy
- Introduces the latest drugs and advancements in the treatment of cancer
- Includes detailed diagrams to give insight to the mechanisms of action
Undergraduate, postgraduate and doctoral students of biomedical sciences, biotechnology, microbiology, biochemistry, immunology, pharmacy, pharmaceutical sciences, bioinformatics, translational research, medical sciences stream. Professional working in oncology with a broad range of cancer treatments looking for updated knowledge of newer targeted and immune-based therapies
- Cover image
- Title page
- Table of Contents
- Copyright
- List of contributors
- Preface
- Chapter 1. Biology of cancer: current insights and perspectives
- Abstract
- Introduction
- A perspective on cancer cell
- Epidemiology of cancer
- Clinical features and diagnosis
- Current and emerging treatment strategies
- Modern challenges in cancer therapy
- Emerging/advanced treatment strategies
- Conclusion and future perspectives
- References
- Chapter 2. Evolution of targeted therapies in cancer: opportunities and challenges
- Abstract
- Introduction
- Types of cancer
- Lung cancer
- Breast cancer
- Colorectal cancer
- Brain cancer
- Blood cancer
- Skin cancer
- Cervical cancer
- Targeted therapies in cancer
- Monoclonal antibodies
- Small molecule inhibitors
- Targeted immunotherapy
- Nanomaterials in cancer therapy
- Opportunities and challenges of targeted cancer therapy
- Conclusions
- Acknowledgments
- Conflict of interest
- Glossary words
- Essay type questions
- References
- Chapter 3. Clinical implementation of biomarkers and signaling pathway as novel targeted therapeutics in breast cancer
- Abstract
- Background
- Factors affecting breast cancer
- Classification of breast cancer
- Biomarkers in breast cancer: diagnostic to targeted therapy
- Targeting molecular signaling pathways
- HER2-positive targeted therapies
- HER2-negative targeted therapies
- Targeted therapy as emerging treatment options
- Conclusion and future perspective
- References
- Chapter 4. Targeted therapies in advanced lung cancer—current landscapes and future projects
- Abstract
- Introduction
- What are targeted therapies
- Large molecule inhibitors
- Immunotherapy
- Monoclonal antibodies
- Small molecule inhibitors and their targets
- Conclusion and future perspectives
- Acknowledgment
- References
- Chapter 5. Targeted therapies: emerging biomarkers in advanced melanoma
- Abstract
- Introduction
- Biomarkers in melanoma (prognostic and predictive)
- Malignant melanoma classification, diagnosis and treatment
- Nanotechnology: mechanisms and nanoparticles in melanoma therapies
- Nanosystems for improved targeted therapies in melanoma
- Conclusion
- References
- Chapter 6. Targeting immune checkpoints for cancer therapy
- Abstract
- Introduction
- Immune checkpoints
- Cytotoxic T-lymphocyte-associated antigen-4 signaling pathway: a promising therapeutic target in cancer
- Anti-PD-1/PDL-1 therapy
- Targeting mammalian target of rapamycin pathway for cancer therapy
- Vascular endothelial growth factor pathway in cancer therapy
- Targeting PI3k/Akt pathway
- Targeting mitogen-activated protein kinases network for cancer prevention
- Inhibition of cyclin-dependent kinases for cancer therapy
- Inhibiting epidermal growth factor receptor and human epidermal growth factor receptor 2 for cancer therapy
- Conclusion
- References
- Chapter 7. Glioblastoma targeted therapies: updated approaches from recent biological insights
- Abstract
- Abbreviations
- Introduction
- Various therapies for glioblastoma multiforme
- Conclusion
- References
- Chapter 8. Current trends and future prospects of molecular targeted therapy in head and neck squamous carcinoma
- Abstract
- Abbreviations
- Introduction
- Epidemiology
- Symptoms and pathophysiology
- Diagnosis and prevention
- Therapeutic strategies
- Existing therapies
- Future prospects
- Summary
- References
- Chapter 9. Targeted therapy and drug resistance in gastric and pancreatic cancer
- Abstract
- Targeted therapy and drug resistance in gastric cancer
- Targeted therapy and drug resistance in pancreatic cancer
- References
- Chapter 10. Colorectal cancer heterogeneity and targeted therapy: clinical implications, challenges, and solutions for treatment resistance
- Abstract
- Introduction
- Molecular biology in metastatic colorectal cancer
- Systemic therapy in metastatic colorectal cancer
- Chemotherapy backbone for metastatic colorectal cancer
- Targeted therapy in first-line setting metastatic colorectal cancer
- Anti-VEGF: bevacizumab
- Antiepidermal growth factor receptor: cetuximab, panitumumab
- Immunotherapy
- BRAF-mutated
- KRAS-G12C-mutation in mCRC
- Elderly/frail patients
- Treatment alternatives after first-line
- Anti-VEGF
- Antiepidermal growth factor receptor
- Anti-BRAF+antiepidermal growth factor receptor
- Treatment alternatives in later lines
- Tyrosine kinase inhibitors
- Thymidine-based nucleoside analogs
- Immunotherapy
- Human epidermal growth factor receptor r2-directed therapy
- Rare actionable fusion proteins
- Local ablative therapy
- Conclusion
- References
- Chapter 11. Endometrial cancer: molecular markers and management of advanced-stage disease
- Abstract
- Introduction
- Type 1 versus type 2
- Classification of endometrial cancer on molecular basis
- Molecular markers of endometrial cancer
- Management of endometrial cancer
- Risk factors for endometrial cancer
- Conclusion
- Acknowledgments
- Statements and declaration
- Glossary items
- Essay-type questions
- References
- Index
- No. of pages: 270
- Language: English
- Edition: 1
- Published: July 29, 2023
- Imprint: Academic Press
- Paperback ISBN: 9780443160349
- eBook ISBN: 9780443160356
PM
Pawan Kumar Maurya
Prof. Pawan Kumar Maurya is Dean, School of Life Long Learning & Head of Department of Biochemistry, Central University of Haryana, India. He has done a PhD from the University of Allahabad (A Central University), India & post-doctoral training from Universidade Federal de Sao Paulo-UNIFESP, Brazil; Taipei Medical University (TMU) and National Taiwan University (NTU), Taiwan. He has more than 14 years of teaching and research experience. He is working on biochemical diagnostics, nanomedicine, and clinical biochemistry. He has published over 75 research articles in reputed journals. He has also edited of six books published from Elsevier, USA and Springer-Nature, Singapore. He is recipient of prestigious fellowships: Science without Borders (Government of Brazil) and National Science Council, Taiwan.
Affiliations and expertise
Central University of Haryana, Mahendergarh (Haryana), INDIAVS
Vikas Saini
Dr. Vikas Saini is working as an Assistant professor and Coordinator of Biomedical Sciences program under Department of Vocational Studies and Skill Development, Central University of Haryana, India. His area of interest is Cancer biology and drug discovery. He earned his Ph.D. in biomedical Sciences from Dr. B.R. Ambedkar Centre for Biomedical Research (ACBR), University of Delhi with an emphasis on identifying novel anticancer molecules. He has research experiences in the area of cheminformatics, drug synthesis, and cancer biology. He has more than 4 years of teaching experience and published several research articles and book chapters in reputed journals. He is currently working on testing novel compounds against cancer.
Affiliations and expertise
School of Lifelong Learning, Central University of Haryana, Mahendergarh (Haryana), IndiaRead Treatment Landscape of Targeted Therapies in Oncology on ScienceDirect